These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36183176)

  • 1. Focal cortical dysplasia pathology: diagnostic difficulty, classification, and utility for pathogenesis.
    Kapar O; Gurkan ZM; Dolgun M; Sencer A; Gürses C; Bilgic B
    Neurosurg Focus; 2022 Oct; 53(4):E6. PubMed ID: 36183176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ILAE consensus classification of focal cortical dysplasia: An update proposed by an ad hoc task force of the ILAE diagnostic methods commission.
    Najm I; Lal D; Alonso Vanegas M; Cendes F; Lopes-Cendes I; Palmini A; Paglioli E; Sarnat HB; Walsh CA; Wiebe S; Aronica E; Baulac S; Coras R; Kobow K; Cross JH; Garbelli R; Holthausen H; Rössler K; Thom M; El-Osta A; Lee JH; Miyata H; Guerrini R; Piao YS; Zhou D; Blümcke I
    Epilepsia; 2022 Aug; 63(8):1899-1919. PubMed ID: 35706131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal cortical dysplasia: Updates.
    Pinheiro J; Honavar M
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S189-S197. PubMed ID: 35562149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FCD Type II and mTOR pathway: Evidence for different mechanisms involved in the pathogenesis of dysmorphic neurons.
    Rossini L; Villani F; Granata T; Tassi L; Tringali G; Cardinale F; Aronica E; Spreafico R; Garbelli R
    Epilepsy Res; 2017 Jan; 129():146-156. PubMed ID: 28056425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cortical Dysplasia and the mTOR Pathway: How the Study of Human Brain Tissue Has Led to Insights into Epileptogenesis.
    Lee WS; Baldassari S; Stephenson SEM; Lockhart PJ; Baulac S; Leventer RJ
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review: The international consensus classification of Focal Cortical Dysplasia - a critical update 2018.
    Najm IM; Sarnat HB; Blümcke I
    Neuropathol Appl Neurobiol; 2018 Feb; 44(1):18-31. PubMed ID: 29359399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, imaging, and immunohistochemical characteristics of focal cortical dysplasia Type II extratemporal epilepsies in children: analyses of an institutional case series.
    Knerlich-Lukoschus F; Connolly MB; Hendson G; Steinbok P; Dunham C
    J Neurosurg Pediatr; 2017 Feb; 19(2):182-195. PubMed ID: 27885945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balloon cells promote immune system activation in focal cortical dysplasia type 2b.
    Zimmer TS; Broekaart DWM; Luinenburg M; Mijnsbergen C; Anink JJ; Sim NS; Michailidou I; Jansen FE; van Rijen PC; Lee JH; François L; van Eyll J; Dedeurwaerdere S; van Vliet EA; Mühlebner A; Mills JD; Aronica E
    Neuropathol Appl Neurobiol; 2021 Oct; 47(6):826-839. PubMed ID: 34003514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia.
    Patil VV; Guzman M; Carter AN; Rathore G; Yoshor D; Curry D; Wilfong A; Agadi S; Swann JW; Adesina AM; Bhattacharjee MB; Anderson AE
    Neuropathology; 2016 Apr; 36(2):146-56. PubMed ID: 26381727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep histopathology genotype-phenotype analysis of focal cortical dysplasia type II differentiates between the GATOR1-altered autophagocytic subtype IIa and MTOR-altered migration deficient subtype IIb.
    Honke J; Hoffmann L; Coras R; Kobow K; Leu C; Pieper T; Hartlieb T; Bien CG; Woermann F; Cloppenborg T; Kalbhenn T; Gaballa A; Hamer H; Brandner S; Rössler K; Dörfler A; Rampp S; Lemke JR; Baldassari S; Baulac S; Lal D; Nürnberg P; Blümcke I
    Acta Neuropathol Commun; 2023 Nov; 11(1):179. PubMed ID: 37946310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar PDK1-AKT-mTOR pathway activation in balloon cells and dysmorphic neurons of type II focal cortical dysplasia with refractory epilepsy.
    Lin YX; Lin K; Kang DZ; Liu XX; Wang XF; Zheng SF; Yu LH; Lin ZY
    Epilepsy Res; 2015 May; 112():137-49. PubMed ID: 25847349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathological work-up of focal cortical dysplasias using the new ILAE consensus classification system - practical guideline article invited by the Euro-CNS Research Committee.
    Blümcke I; Mühlebner A
    Clin Neuropathol; 2011; 30(4):164-77. PubMed ID: 21726501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies.
    Liu J; Reeves C; Michalak Z; Coppola A; Diehl B; Sisodiya SM; Thom M
    Acta Neuropathol Commun; 2014 Jul; 2():71. PubMed ID: 25005575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal cortical dysplasias in temporal lobe epilepsy surgery: Challenge in defining unusual variants according to the last ILAE classification.
    Martinoni M; Marucci G; Rubboli G; Volpi L; Riguzzi P; Marliani F; Toni F; Naldi I; Bisulli F; Tinuper P; Michelucci R; Baruzzi A; Giulioni M
    Epilepsy Behav; 2015 Apr; 45():212-6. PubMed ID: 25812941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SLC35A2 somatic variants in drug resistant epilepsy: FCD and MOGHE.
    Elziny S; Crino PB; Winawer M
    Neurobiol Dis; 2023 Oct; 187():106299. PubMed ID: 37739137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR pathway activation in focal cortical dysplasia.
    Kumari K; Sharma MC; Kakkar A; Malgulwar PB; Pathak P; Suri V; Sarkar C; Chandra SP; Faruq M
    Ann Diagn Pathol; 2020 Jun; 46():151523. PubMed ID: 32325422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances of pathological research and classification in malformations of cortical development associated with refractory epilepsy].
    Fu YJ; Piao YS
    Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):419-424. PubMed ID: 38678320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinico-pathological characterisation of focal cortical dysplasia type IIb genetically defined by MTOR mosaicism.
    Wang Y; Yu T; Blümcke I; Cai Y; Sun K; Gao R; Wang Y; Fu Y; Wang W; Wang Y; Zhang G; Piao Y
    Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12874. PubMed ID: 36544434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A distinct clinicopathological variant of focal cortical dysplasia IIId characterized by loss of layer 4 in the occipital lobe in 12 children with remote hypoxic-ischemic injury.
    Wang DD; Piao YS; Blumcke I; Coras R; Zhou WJ; Gui QP; Liu CC; Hu JX; Cao LZ; Zhang GJ; Lu DH
    Epilepsia; 2017 Oct; 58(10):1697-1705. PubMed ID: 28833053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic DNA methylation distinguishes subtypes of human focal cortical dysplasia.
    Kobow K; Ziemann M; Kaipananickal H; Khurana I; Mühlebner A; Feucht M; Hainfellner JA; Czech T; Aronica E; Pieper T; Holthausen H; Kudernatsch M; Hamer H; Kasper BS; Rössler K; Conti V; Guerrini R; Coras R; Blümcke I; El-Osta A; Kaspi A
    Epilepsia; 2019 Jun; 60(6):1091-1103. PubMed ID: 31074842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.